Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26627848 | 0.97 | PIK3CA (0.32) | PIK3CAKDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL25599878 | 0.96 | KDM4E (0.33) | PIK3CAKDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL26630769 | 0.94 | PIK3CA (0.31) | PIK3CAKDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL26627834 | 0.94 | PRKDC (0.33) | PIK3CAKDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL26627795 | 0.93 | PRKDC (0.31) | KDM4EALDH1A1HPGDEGFRTNIK | |
| SCHEMBL26627757 | 0.93 | KDM4E (0.33) | PIK3CAKDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL25599974 | 0.92 | PRKDC (0.34) | KDM4EALDH1A1LMNARAB9A | |
| SCHEMBL25599970 | 0.92 | EGFR (0.34) | PIK3CAKDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL25599977 | 0.92 | PIK3CA (0.30) | PIK3CA | |
| SCHEMBL26627815 | 0.91 | PRKDC (0.34) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340318-A1 | PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES | HOYA LENS THAILAND LTD. (TH) | 2023-10-26 | — | — | US | disclosed |
| EP-4198102-A1 | PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES | Hoya Lens Thailand Ltd. (TH) | 2023-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340318-A1 | PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES | NR2E3, CRY1, RPS10 | PIK3CA 3076/4885KDM4E 3270/4885NPC1 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.